ASX:AT1

Atomo Diagnostics Stock Forecast, Price & News

Add

Compare

Today's Range N/A

50-Day Range N/A

52-Week Range N/A

VolumeN/A

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Receive AT1 News and Ratings via Email

Sign-up to receive the latest news and ratings for Atomo Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

About Atomo Diagnostics

Atomo Diagnostics Limited researches, designs, develops, manufactures, and sells medical devices for blood-based rapid testing for professional use and self-testing. The company offers AtomoRapid RDT platforms to suit various blood-based lateral flow test assays and are appropriate for a range of applications, including screening for chronic conditions and detection of infectious diseases. Its rapid test devices are used by healthcare professionals and by consumers to screen for a range of diseases and medical conditions, including HIV infection. The company has operations in Europe, Asia, Africa, and Central and South America. Atomo Diagnostics Limited was founded in 2010 and is headquartered in Leichhardt, Australia.

The Atomo (ASX:AT1) share price has shot up 9%. Here’s why
July 28, 2021 | msn.com

Here’s why the Atomo (ASX:AT1) share price is soaring 10%
July 27, 2021 | fool.com.au

How Much Did Atomo Diagnostics'(ASX:AT1) Shareholders Earn From Share Price Movements Over The Last Year?
July 4, 2021 | finance.yahoo.com

Atomo Diagnostics Limited's (ASX:AT1) Shift From Loss To Profit
July 4, 2021 | finance.yahoo.com

Last Orders: ASX edges slightly lower amidst COVID fears
June 28, 2021 | msn.com

Atomo Diagnostics shares surge after COVID test is authorised by the FDA
June 28, 2021 | msn.com

Atomo Diagnostics (ASX:AT1) share price rockets 59% on COVID-19 test update
June 28, 2021 | msn.com

Meet Lumos Diagnostics – the latest diagnostic testing company that’s listing on the ASX and wants an FDA green light
June 10, 2021 | msn.com

What Percentage Of Atomo Diagnostics Limited (ASX:AT1) Shares Do Insiders Own?
May 5, 2021 | finance.yahoo.com

The Atomo (ASX:AT1) share price is soaring today. Here’s why
April 29, 2021 | msn.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange ASX
Industry Medical Devices
Sub-IndustryN/A
SectorMedical
Current SymbolASX:AT1
Previous Symbol
CUSIPN/A
CIKN/A
Webatomodiagnostics.com
Phone61 2 9099 4750
EmployeesN/A
Year FoundedN/A

Sales & Book Value

Annual Sales$9.01 million
Price / Sales0.00
Cash FlowN/A
Price / Cash FlowN/A
Book ValueA$0.06 per share
Price / BookN/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.00 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Atomo Diagnostics.

0.0 Community Rank

Outperform Votes
Atomo Diagnostics has received 0 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Atomo Diagnostics has received 0 “underperform” votes. (Add your “underperform” vote.)

MarketBeat's community ratings are surveys of what our community members think about Atomo Diagnostics and other stocks. Vote “Outperform” if you believe AT1 will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AT1 will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Atomo Diagnostics does not currently pay a dividend.
Dividend Growth
Atomo Diagnostics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Atomo Diagnostics insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Atomo Diagnostics (ASX:AT1) Frequently Asked Questions

What stocks does MarketBeat like better than Atomo Diagnostics?

Wall Street analysts have given Atomo Diagnostics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Atomo Diagnostics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Atomo Diagnostics' key executives?

Atomo Diagnostics' management team includes the following people:

Mr. John Michael Kelly, Founder, CEO, MD & Director
Mr. William Edward Souter BCom, LLB (Adel), IPAA, Chief Financial Officer
Mr. Mark Smith, Chief Operating Officer
Mr. Fabio Baglioni, Chief Commercial Officer
Ms. Gillian Maria Nairn, Company Sec.

Who are some of Atomo Diagnostics' key competitors?

Some companies that are related to Atomo Diagnostics include 4DMedical (4DX), Adherium (ADR), ADM Tronics Unlimited (ADMT), Allegra Orthopaedics (AMT), Analytica (ALT), AnteoTech (ADO), Anteris Technologies (AVR), Asensus Surgical (ASXC), AVITA Medical (AVH), Azure Healthcare Limited (AZV.AX) (AZV), Cannabix Technologies (BLO), CleanSpace (CSX), Cochlear (COH), Cochlear (CHEOY) and Cochlear (CHEOF).
View all of AT1's competitors.

What is Atomo Diagnostics' stock symbol?

Atomo Diagnostics trades on the ASX under the ticker symbol "AT1."

How much money does Atomo Diagnostics make?

Atomo Diagnostics has a market capitalization of $0.00 and generates $9.01 million in revenue each year.

What is Atomo Diagnostics' official website?

The official website for Atomo Diagnostics is atomodiagnostics.com.

How can I contact Atomo Diagnostics?

The company can be reached via phone at 61 2 9099 4750.

This page was last updated on 7/29/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.